Besides, the ICBs such as durvalumab have shown good survival benefits in stage III NSCLC (8), but due to the obvious heterogeneity in immune features (32), the PD-L1 expression, as well as TMB, are not good predictors of immunotherapy efficacy, which is different from their application in stage IV of NSCLC (7). This evidence concerns the gene CD274 and non-small cell lung carcinoma.